Angiotensin-converting enzyme (ACE) is important in the regulation of blood pressure (BP). Two tripeptides that inhibit ACE, isoleucyl-prolyl-proline (Ile-Pro-Pro) and valyl-prolyl-proline (Val-Pro-Pro), have been isolated from certain sour milks. The aim of the study reported was to evaluate the effect on BP in subjects with mild hypertension of a new sour milk containing tripeptides. The initial number of subjects was 60 (36 men, 24 women). Among the criteria for inclusion in the study were systolic BP (SBP) between 140 and 180 mmHg and/or diastolic BP (DPB) between 90 and 110 mmHg, without antihypertensive drug therapy. There were two study periods with a washout period between. All subjects were given 1.5 dl per day of a placebo (regular sour milk) or of the active product, a milk that had been fermented with Lactobacillus helveticus bacteria and contained 2.4-2.7 mg of Ile-Pro-Pro and 2.4-2.7 mg of Val-Pro-Pro per 1.5 dl. In the first phase, SBP fell 16 mmHg from baseline in the active group, 2 mmHg more than in the placebo group (P ¼ 0.0668) and no difference in DBP (P ¼ 0.92). There was a statistically significant downward trend both in SBP and DBP (P ¼ 0.0001). During the second phase, SBP fell 11 mmHg in the active group (P ¼ 0.008). The reduction in SBP was significantly larger in active than placebo group (P ¼ 0.012). In the crossover analysis combining both phases, SBP fell on average 2.6715.9 mmHg more on the active product compared with the placebo product, but this difference was not statistically significant (P ¼ 0.3111). The difference in DBP, 1.078.3 mmHg between the two test products was not significant either (P ¼ 0.4431). In conclusion, the ingestion of sour milk fermented by L. helveticus bacteria and that containing ACE inhibitory tripeptides seems to lower BP modestly.
Background
Angiotensin-converting enzyme (ACE) is important in the regulation of blood pressure (BP).
1 ACE catalyses the formation of angiotensin I to angiotensin II in the renin-angiotensin system. The angiotensin II raises BP and thus inhibition of ACE can decrease BP. Several tripeptides that inhibit ACE have been isolated from food.
2-5 Nakamura et al 6 isolated and identified two such tripeptides, isoleucyl-prolyl-proline (Ile-Pro-Pro) and valyl-prolyl-proline (Val-Pro-Pro). These peptides were isolated from sour milk (Calpis s ), which was fermented with Lactobacillus helveticus and Saccharomyces cerevisiae bacteria.
Long-term administration of Ile-Pro-Pro and ValPro-Pro has been shown to prevent development of hypertension in spontaneously hypertensive rats 7, 8 and to reduce BP by single oral administration. 9 Ile-Pro-Pro and Val-Pro-Pro have also been shown to lower BP in mildly hypertensive subjects. [10] [11] [12] In a controlled trial Hata et al 10 showed that ingestion of Calpis s (Calpis Food Industry Co., Tokyo, Japan) for 8 weeks significantly reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP). In another 8-week study Seppo et al 12 found that Evolus s (Valio Ltd, Helsinki, Finland), a fermented milk, which also contains Ile-Pro-Pro and Val-ProPro and is produced by fermentation with L. helveticus LBK-16 H, reduced BP in mildly hypertensive subjects. In a 21-week study SBP and DBP fell significantly more in a group that had ingested Evolus s than in a control group (SBP À6.773.0 mmHg, P ¼ 0.030, DBP À3.671.9 mmHg, P ¼ 0.059 ). 11 In the study reported here, the aim was to determine the effects on BP in subjects with mild hypertension of ingestion of a sour milk product containing tripeptides during fermentation.
Materials and methods
The study was carried out in Kuopio, Finland, during the first half of 2000. A total of 60 subjects (36 men, 24 women) were randomised into the trial. Among the criteria for inclusion were SBP between 140 and 180 mmHg and/or DBP between 90 and 110 mmHg (means of two measurements on consecutive days), and no use of antihypertensive drugs at the time of entry into the study. Criteria for exclusion were existence of secondary hypertension or any serious disease, allergy to cow's milk, a history of alcohol abuse, and pregnancy.
BP was always measured during the morning, preferably between Tuesday and Thursday. Subjects were instructed to avoid vigorous exercise, smoking, drinking coffee or eating heavily for half an hour before measurement. BP was measured from the right arm, with subjects in a sitting position, after 10 min of rest from the time the cuff had been placed on the arm. All measurements were made by the same experienced nurse, using the same sphygmomanometer throughout the study. BP was measured twice at 2-min intervals in each case. A third measurement was undertaken if the difference between two measurements was 5 mmHg or more. The data analysed were the means of the two BP values.
Subjects, wearing light indoor clothing and no shoes, were also weighed at the time of each BP measurement.
Baseline characteristics of the subjects are shown in Table 1 . The mean body mass index (BMI) is high. In all, 23% of the participants were of normal weight (BMIo25 kg/m 2 ), 45% were overweight (25pBMIp 30 kg/m 2 ) and 32% were obese (BMI430 kg/m 2 ). Seven subjects (12%) smoked. In total, 45% ate food prepared at home with low-sodium mineral salt.
The subjects were randomised into two groups. A crossover study was conducted. The first period lasted for 8-10 weeks. BP was measured during weeks 0, 3, 6, 8, 9 , and 10. This was followed by a washout period of 3-4 weeks. The second phase lasted for 5-7 weeks. BP was measured during weeks 0, 3, 4, and 5.
Originally, the study was planned as a parallelgroup design with no crossover. However, the independent interim analysis of the BP changes from baseline to week 9 showed that the BP reduction in all study subjects from baseline to week 3 was larger than estimated in the planning for the active group. This reduction was maintained up to the week 9. Thus, our original estimate for statistical power to identify possible differences between groups appeared not to be sufficient due to this 'placebo effect'. Therefore, it was decided to continue the trial with a crossover design to gain more statistical power. Since the original consent was asked from the study subjects for the initial 10-week study phase, a repeat consent had to be obtained for the second test phase.
One of the original 60 subjects dropped out during the third week, another during the ninth week. Of the 58 subjects who completed the first study period, 40 were willing to continue on a crossover basis. Of these, 18 had ingested the active product, 22 placebo. Thus, there was no imbalance between randomisation groups in the willingness to join the second test phase. One subject dropped out during the first week of the second study period.
Study products
Each subject was given 1.5 dl/day of the active product or placebo (regular sour milk). The active Groups and products were coded. Neither the study nurse nor the subjects knew which was the active product and which the placebo product, that is, the study was conducted on a double-blind basis. Participants were asked to keep records of the products they ingested. The study nurse checked these records during each visit. According to these records, the participants ingested products punctually.
Statistical analyses
First study period
The within-subject changes in blood pressure from baseline were calculated at different time points. Analysis of variance for repeated measurements was used to compare the study groups with respect to the changes in blood pressure after 3, 6, 8, 9, and 10 weeks of treatment, and to test the time effect and the interaction between time and treatment. As a secondary analysis the changes after 3, 6, 8, 9, and 10 weeks of treatment were compared between study groups by t-test for independent samples. Treatment differences with 95% confidence intervals (CIs) were given. One subject in placebo group was withdrawn after 3 weeks and was not included to the statistical analysis. One subject in placebo group was withdrawn after 9 weeks and for that subject the last BP measurements were carried forward to week 10. The final sample size in all analyses is 59 (active n ¼ 30; placebo n ¼ 29).
Second study period
The repeated measurements after baseline were at weeks 3, 4, and 5. The timing was different from the first study phase, and therefore, the data were first analysed independently of the first part of the study. Analysis of variance for repeated measurements was used to compare the study groups with respect to the changes in blood pressure after 3, 4, and 5 weeks of treatment. As a secondary analysis, the changes were compared between study groups by t-test for independent samples. One subject was withdrawn before week 3 and was not included to the analysis. The final sample size was 39 (active n ¼ 17; placebo n ¼ 22).
Crossover analysis
In order to make the study periods I and II comparable, the BP responses were estimated using the mean of weeks 3 and 6 from the first study period and the mean of weeks 4 and 5 from the second study period. Analysis of variance for repeated measurements was used to test the period effect, the carryover effect and the group effect.
Results
Weights of the subjects fell significantly during the first study period, on average by 0.571.9 kg (P ¼ 0.0484). There was no statistically significant difference between the two treatment groups. Weight change during the second study period was not significant.
The mean changes in SBP and DBP during the first study period are shown in Figure 1 and Table 2 . By the time of the last visit, SBP had fallen on average by 16 mmHg from baseline in the group that had ingested the active product, 2 mmHg more than in the placebo group. There was a statistically significant downward trend in both in SBP and DBP (time effect P ¼ 0.0001). The estimated mean change in SBP from baseline was 9.9 mmHg in those who had consumed the placebo product, 11.2 mmHg in those who had consumed the active product. The treatment difference was 1.3 mmHg (95% CI À6.2 to 3.6, P ¼ 0.59). For DBP, the corresponding mean changes were 7.9 mmHg in those who had consumed the placebo product and 8.1 mmHg in those Sour milk containing tripeptides and BP J Tuomilehto et al who had consumed the active product. Treatment difference was À0.1 mmHg (95% CI À3.0 to 2.7,
The mean changes in SBP and DBP during the second study period are shown in Figure 2 and Table 3 . SBP levels also fell statistically significantly during the second study period (P ¼ 0.0003). However, the difference in SBP changes between groups was not significant (P ¼ 0.10). The mean change from baseline is þ 3.9 mmHg in those who had ingested placebo and À2.5 mmHg in those who had ingested the active product. The resulting difference between products was À6.4 mmHg (95% CI À14.2 to 1.4).
The corresponding changes in relation to DBP were À1.9 mmHg in those who had ingested the placebo product and À3.4 mmHg in those who had ingested the active product. The treatment difference between products was 1.5 mmHg (À5.1 to 2.1,
The crossover analysis relates only to the 39 subjects who participated in both study periods. Both SBP and DBP were lower during the second study period than during the first study period. There was also a significant carryover effect (P ¼ 0.031) in relation to SBP, that is, an effect of ingesting the active product may still have been evident during the second study period (Table 4) .
Ignoring this significant carryover effect, SBP was on average 1.9 mmHg lower in those who had ingested the active product than in those who had ingested placebo. However, this difference was not significant (95% CI À5.1 to 1.3, P ¼ 0.24). The Sour milk containing tripeptides and BP J Tuomilehto et al treatment difference in relation to DBP was À0.9 mmHg (95% CI À2.4 to 0.6, P ¼ 0.24).
Discussion
The results of this controlled study show that the active sour milk containing tripeptides lowered BP slightly in hypertensive subjects. The effect on DBP was minor. During both study periods, SBP fell more in those who had ingested the active product than in those who had ingested placebo, but the difference was statistically significant only in relation to the second study period. The reductions in SBP in those who had ingested the active product were similar during both study periods (16 and 11 mmHg). On the other hand the differences between the changes in BP during the two study periods reflect the greater reductions in BP in those who had ingested placebo during the first study period than during the second study period (SBP change À14 vs þ 2 mmHg, respectively). There was a significant reduction in BP in those who ingested placebo during the first study period. Similar reductions have been reported in earlier studies. 13 This is largely a result from an accustomisation of the participants with BP measurement and study personnel. Also, the regression to the mean results in lowering in BP values in repeated measurements in subjects whose initial values were higher than the population mean. These two phenomena complicate controlled trials of agents intended to reduce BP. It is also possible that seasonal variation in BP affected findings during the first study period. The latter started in midwinter, when BP levels are known to be highest. 14, 15 The 5-week visit during the second study period occurred just before midsummer in the case of many 
Sour milk containing tripeptides and BP J Tuomilehto et al subjects. In Finland, summer vacations start then. It was therefore not feasible to prolong the second study period beyond 5 weeks. About a third of the subjects who took part in the first study period did not continue into the second phase. This may be the reason for the greater fall in SBP, by 3716 mmHg, in those who had ingested the active product than in those who had ingested placebo is not statistically significant. For such a change in BP with the s.d. observed to be statistically significant, the number of subjects in the trial needed for the trial would be approximately 200 persons. For the estimation of the sample size, we used results from an earlier Japanese study. 10 At the time, it was the only controlled trial in this connection in human subjects. In the Japanese study, the reduction in SBP was 14 mmHg after ingestion of sour milk to which tripeptides had been added. We assumed that we might see a reduction of 6-7 mmHg and calculated the number of subjects required accordingly.
It has been shown that Ile-Pro-Pro and Val-Pro-Pro are absorbed intact via the gastrointestinal tract. 16, 17 It has been suggested that the mechanism of the antihypertensive effect exerted by such tripeptides is ACE inhibition. 6, 7 Sipola et al 7 reported that the BP at the end of a trial in rats that had consumed peptide-enriched fermented milk was 21 mmHg lower than the BP of rats that had consumed water, and 10 mmHg lower than the BP of rats that had consumed Calpis s . 7 The peptide-enriched fermented milk we studied contained more peptides than Calpis.
s The ACE-inhibitory effect of tripeptides in sour milk is much smaller than that of any antihypertensives that acts mainly by means of ACE inhibition. A milk product with added tripeptides could not therefore be the only treatment of severe hypertension. It has been suggested that tripeptides in sour milk could also reduce BP in other ways, for example, through regulation of opioid receptors. However, further studies are needed in these connections. An effect on BP appeared only after a few weeks in the subjects who ingested the active product. This supports the idea that its effect is related to ACE inhibition. Antihypertensive drugs that inhibit ACE begin to lower BP only after they have been taken for a few weeks. It is also known that BP does not decline following administration of ACE inhibitors in some individuals. An ACE inhibitor will only affect high BP if the hypertension has an appropriate cause.
In the Japanese study of the effect of ingestion of sour milk containing added tripeptides, the mean SBP of subjects decreased by 14 mmHg and the mean DBP by 7 mmHg. The product was slow to take effect. Reductions in BP were seen only after a few weeks of ingestion of the product. Most subjects in the Japanese study were also taking antihypertensive drugs. Changes in BP in such subjects may be likely to be larger than in subjects like ours, who were suffering from only mild hypertension. It has been shown in comparative studies that the effect of nonpharmacological measures becomes greater as BP level increases. 18 The antihypertensive effect of the product we studied ought therefore to be determined in subjects with BP levels higher than in our subjects. However, individuals with BP levels higher than those in our subjects will have been advised to take antihypertensive medication. Medical treatment complicates study implementation and analysis of results. Nevertheless, more studies in different groups of the effects on BP of the sour milk product we studied are needed to allow its action to be more precisely characterized.
A reduction in SBP by 3 mmHg is significant from a public health point of view, since decreasing elevated BP is a cornerstone of prevention of cardiovascular disease. Results of large-scale controlled trials of antihypertensive drug have demonstrated that a mean reduction in DBP by 6 mmHg reduces risk of stroke by 40%, and risk of myocardial infarction by 20%. 19 Such a reduction in DBP corresponds to a decrease in SBP by 9-10 mmHg. It has been estimated that a decrease in SBP by 3 mmHg would reduce risk of stroke by 10-13%, and risk of myocardial infarction by 7%, over a 5-year period. ACE inhibition has been shown to reduce incidence of cardiovascular disease in individuals at high risk of such disease. 20 This beneficial effect of ACE inhibition seems to be only partly related to reductions in BP, because in the HOPE trial outcomes were also better in normotensive subjects treated in this way. ACE inhibition may therefore have other beneficial effects. 21 Average reductions in SBP and DBP in the HOPE trial in patients taking low doses of an ACE inhibitor were 3 and 2 mmHg, respectively, that is, similar to the reductions we saw in our study. When nonpharmacological means of reducing BP have been studied in individuals with mild hypertension reductions in SBP has been 2-5 mmHg, in DBP 1-2 mmHg. 22, 23 Some studies of this kind have involved multiple interventions. It has also been estimated that a reduction in sodium intake of 100 mmol/24 hours should result in reductions in BP of similar magnitudes. In a recent nonpharmacological study by us DBP decreased more during the first year in a group in relation to which intervention was undertaken than in a group receiving normal care but differences after two years are not significant. However, in subjects who received no antihypertensive drugs, differences after 2 years are statistically significant in relation to both DBP (À2.9 mmHg) and SBP (À4.0 mmHg). 24 The effects reported are accordingly similar to the effects seen in the study reported here. Although our original calculations indicated that the number of subjects in our study should have been adequate for the effect anticipated to have stood a reasonable chance, if real, of being shown to be statistically significant, in the event a lesser effect was found. Inclusion of more subjects would therefore have been desirable. We therefore suggest repetition of the study in a greater number of subjects.
International and national guidelines relating to the treatment and prevention of hypertension emphasise and recommend use of nonpharmacological measures. In Finland, for instance, the requirements of the Social Insurance Institution of Finland relating to approval of reimbursement of costs of antihypertensive drug treatment state that the hypertension must have been treated using nonpharmacological means for several months following diagnosis. There is, however, no definition of nonpharmacological treatment. It obviously includes weight reduction in the obese, increase in physical activity, and reductions in salt, alcohol and saturated fat intakes. All of these can reduce BP but not necessarily in each individual. Many nonpharmacological means of treatment need to be employed simultaneously because the causes of hypertension are many. A combined effect of altering several lifestyle-related factors has recently been shown to prevent worsening of impaired glucose tolerance in type II diabetes. Consumption of foods, such as sour milk containing tripeptides that have been shown to reduce BP, may be another useful means of treating and preventing hypertension.
We conclude that the sour milk with added tripeptides that we tested lowered BP modestly in subjects with mild hypertension. The effect on DBP was particularly modest. The mean SBP decreased 3716 mmHg after ingestion of the active product compared with the placebo product. Although this reduction in BP was not statistically significant, this kind of change in BP is clinically significant. Reductions in BP of the kind observed would result in a reduction in the risk of stroke by over 10% over a 5-year period, and in the risk of myocardial infarction of almost 10% over a 5-year period. 25 For a change in BP of the magnitude observed to stand a reasonable chance of being shown to be statistically significant the study would have needed to be conducted in some 200 subjects. More studies of the active product we tested need to be undertaken. Our results suggest that it has beneficial effects on BP in persons with mild hypertension. The results of studies in animals show that products of this kind can reduce BP, mainly because of their tripeptide contents. The assumption is that the tripeptides have mild inhibitory effects on ACE. However, other mechanisms of action cannot be excluded.
